Sequoia Capital China backs $16m round for biotech company Cullgen

Sequoia Capital China backs $16m round for biotech company Cullgen

Photo by Louis Reed on Unsplash

Sequoia Capital China has participated in a $16-million Series A round for US-based drug discovery company Cullgen Inc, according to a statement.

Chinese healthcare-focused investment firm HighLight Capital also participated in the funding round. Following the investment, Sequoia will get a seat on Cullgen’s board.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter